Ocugen hasn't stated yet when a potential late-stage study of Covaxin could start. Histogenics shareholders then received about 14% of the company, according to the merger prospectus. Theres an opportunity here. *Average returns of all recommendations since inception. With this, the newly formed Ocugen initiated a 60:1 reverse stock split. But realizing value in practice usually is a difficult endeavor. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. The Motley Fool has a disclosure policy. However, when that occurred, Ocugen stock lost most of its value. And its at least possible that OCGN could wind up being a winner. Biotech companies have emerged from similar levels to become huge winners, as evidenced simply by looking at some of the best biotech stocks for 2019. Instead of buying a piece of the S&P 500 or Nasdaq or even better, a common sense mega-holding like Apple (NASDAQ:AAPL) or Amazon investors in OCGN stock took on a high-risk investment and for months saw negative returns. To be sure, current cash isnt enough. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Admittedly one could argue that it could have been bought for a quarter and sold for 75 cents, but hindsight is 20/20 in all of these names. So far, that merger hasnt worked out for Histogenics former shareholders. One thing seems certain, however:Ocugens fate as an investment is closely tied to the ultimate outcome of Covaxin. Theres even room for more lines. Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The agreement stipulates Ocugen will hold the vaccines U.S. rights, and the remaining details are expected to be finalized over the coming weeks. Healthy companies do not undergo 1-for-60 reverse stock splits like this one did in September 2019. quotes delayed at least 15 minutes, all others at least 20 minutes. It took Moderna roughly 10 months from the initiation of the late-stage study for its COVID-19 vaccine to the point where the company filed for full FDA approval. The median estimate. Copyright 2023 InvestorPlace Media, LLC. Can you feel the ground moving beneath your feet? Why Everyone Is Investing in 5G All WRONG, Americas #1 Stock Picker Reveals His Next 1,000% Winner, Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company, Radical New Battery Could Dismantle Oil Markets. Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Buy These 2 Stocks in 2023 and Hold for the Next Decade, 2 Stocks That Are About to Make Their Shareholders Richer, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, the company's fourth-quarter conference call last month, Copyright, Trademark and Patent Information. But it does mean something. Theres even room for more lines. If it goes down, your loss won't be as great as it would be if you held onto all of your shares. However, even from this limited vantage point, OCGN appears destined to fail. OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Ocugen In 2021, Beyond: Optimism about Covaxin coupled with massive short squeezes in a handful of popular social media stocks sent Ocugen shares skyrocketing up to as high as $18.77 in February 2021. Typically, I care little about financials with biotechs. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA. Investors appear to expect that Bharat's big win for Covaxin in India could translate to success for Ocugen in the U.S. On Dec. 22, Ocugen and Bharat announced a binding letter of intent to jointly develop Covaxin for the U.S. market. How long might it take for Ocugen to win full FDA approval for Covaxin? It means that raising capital will be more difficult going forward. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. UPDATE 1-Soccer-Traore on target as Wolves stun wasteful Spurs, Peruvian communities to resume blockade of crucial "mining corridor", One student loan forgiveness effort 'hasnt gotten the attention it deserves': expert, RPT-Death toll in strike on Ukraine's Zaporizhzhia rises to 11 - officials, Soccer-Traore on target as Wolves stun wasteful Spurs. The reverse merger with Histogenics was a disappointment, but the purchase price for the NeoCart intellectual property suggests that company had little chance of survival on its own. Copyright 2023 InvestorPlace Media, LLC. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Pricing likely would be favorable, given the lack of alternative treatments. Ocugen announced in late Decemberit had signed a letter of intent to co-develop COVID-19 vaccine candidate Covaxin along with Indian pharmaceutical company Bharat Biotech. quotes delayed at least 15 minutes, all others at least 20 minutes. That's right -- they think these 10 stocks are even better buys. The Motley Fool->. The stock had gained some traction after they announced the Ocugen merger in April. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. Honestly, OCGN stock is unlikely to survive. Do not expect a recovery in Ocugen stock. Ocugen Chairman and CEO Shankar Musunuri Ocugen The company's stock opened at $8.24 per share Tuesday, up 96 cents. Literally, zero. The company stated that it will pursue a path to file for full FDA approval of Covaxin. Copy and paste multiple symbols separated by spaces. An unprofitable biotech that focused on commercializing therapies to cure blindness prior to the present pandemic, Ocugen ( OCGN) stock took on a new life on December 22, when it announced. Unfortunately, both the merger and the reverse split have failed to stem the decline of former Histogenics stock. Ocugen executives even sounded cautiously optimistic in the company's fourth-quarter conference call last month. Copyright Thats the thing with these low-priced penny stocks. Our 3 Top Picks. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Its certainly possible. Invest better with The Motley Fool. According to the prospectus, the combined company posted an operating loss of roughly $30 million in 2018. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. That's right -- they think these 10 stocks are even better buys. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. However, an EUA in India doesn't mean that Covaxin is a slam dunk to win EUA in the U.S., as well. Bharat Biotech has a history of successful vaccine commercialization in South Asia. Investors should definitely reevaluate Ocugen's prospects in light of the company's bad news announced last week. Objective investors could have clearly seen then that there actually were significant reasons to be concerned. Ocugen Inc. is a clinical stage biopharmaceutical company. Don't overlook another approach, especially if you're still sitting on a nice gain even after last week's major sell-off. Ocugen abandoned its pursuit of a U.S. EUA for Covaxin in immunizing adults last year. The company has no revenue, runs an annual deficit, and does not generate positive free cash flow. For now, the biggest near-term hope for Covaxin may be that Canada or another developed economy will buy the vaccine to share with developing nations. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Type a symbol or company name. Probably the most important thing to do after Ocugen's crash, though, is to identify lessons learned and apply them to future investing decisions. The first is that Ocugen is facing potential delisting from the NASDAQ given that its share price still sits well below $1. Here are three prudent steps to take. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. Even though Ocugen did raise $25 million in a private placement, the story behind OCU300 clearly was not enough to support an initial public offering on its own. Its worth emphasizing: Ocugen stock is a play with enormous risk. Unfortunately, when the market bounced in late March 2020, Ocugen kept heading lower. Almost all the headlines about Ocugen in the past year have been about the companys COVID-19 vaccine candidate. Keith Speights has no position in any of the stocks mentioned. That product drives the current bull case for Ocugen stock. Ramakanth believes the broad immunity targeting different components of the virus could potentially provide better protection against emerging mutant viruses, such as the one currently circulating in the UK. With this in mind, in the Phase 1 study, COVAXIN has shown robust antibody responses against spike (S1) protein, receptor-binding domain (RBD) and the nucleocapsid (N) protein of SARS-CoV-2. Investors were hopeful that the small drugmaker would be able to win U.S. 86% of retail CFD accounts lose money, Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023, Ocugen upgraded at Chardan citing attractive entry point ahead of catalysts, Analysts Are Bullish on These Healthcare Stocks: Theratechnologies (THTX), Ocugen (OCGN), Ocugen (OCGN) Gets a Buy from H.C. Wainwright, Mizuho Securities Sticks to Their Buy Rating for Ocugen (OCGN), Ocugen (OCGN) Q4 2022 Earnings Call Transcript, Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket, Registration on or use of this site constitutes acceptance of our. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. InvestorPlace - Stock Market News, Stock Advice & Trading Tips. MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. Concerns about the delta variant, the potential need for annual booster shots and the possibility of expanding the vaccines to children have investors hopeful that Covaxin will still eventually be a huge payoff for Ocugen. MALVERN, Pa., May 29, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular diseases, today announced that it will present at the 2018 BIO International Convention, taking place June 4-7, 2018, in Boston. Maybe it pans out for Ocugen and I wish the team (and its investors) the best of luck. Making the world smarter, happier, and richer. As of this writing, Matt did not hold a position in any of theaforementioned securities. market." The stock dropped as low as 26 cents during the height of the pandemic fears in March 2020. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. Do Not Sell My Personal Information (CA Residents Only). Covaxin doesn't have an advantage in terms of dosing compared to these leading vaccines. 1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell, 3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street, 2 Reasons to Avoid a Roth 401(k) for Your Retirement Savings, Warren Buffett's Latest $2.9 Billion Buy Brings His Total Investment in This Stock to $66 Billion in 4 Years, Want $1 Million in Retirement? Some of the names will rally big, putting together epic squeezes that can double or triple the stock prices in just a few days. The company initiated its Phase 3 trial of OCU300 back in July 2018. If were playing that game then Im buying LEAP call options on Apple and Amazon in March. Article printed from InvestorPlace Media, https://investorplace.com/2020/01/ocugen-stock-faint-heart/. Thats one of the best rallies weve seen in that amount of time (95 trading sessions, 136 days). Part of the proceeds will be used to support its partnership with Bharat. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! That's not going to happen now. The sale of NeoCart, which still is pending, can bring in another $8 million, based on the current agreement. This is most likely a result of the stocks meteoric rise and analysts inability to turnaround new price targets so quickly. It is very important to do your own analysis before making any investment. The Motley Fool recommends Moderna Inc. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their investment. Please check your download folder. For most of its history, what we now know as Ocugen stock was Histogenics, a cell therapy company focused on orthopedics. Nano-cap biotech play Ocugen has an intriguing story and a ton of risk. A $30 million market capitalization doesnt mean Ocugen has no chance. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. The average Ocugen stock price for the last 52 weeks is 2.10. The worst news was that another late-stage clinical study will likely be required to support the regulatory filing. Article printed from InvestorPlace Media, https://investorplace.com/2019/12/no-pathway-forward-for-ocugen-stock/. Cost basis and return based on previous market day close. ET by MarketWatch Automation Ocugen Inc. stock falls Tuesday, underperforms market Feb. 21, 2023 at 5:14. *ALL INFO ABOUT THE BIKE AND GEAR USED DOWN BELOW**If not listed it's left stock*BIKE: 2018, BMW R NINET SCRAMBLER.EXHAUST: Akrapovic Headers, Uni. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Keith Speights owns shares of Pfizer. At the time, Ocugen was left for dead. Keith Speights has no position in any of the stocks mentioned. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. On June 10, though, Ocugen announced that the U.S. Food and Drug Administration (FDA) had effectively shut the door on an EUA filing. Generally, financial analysts struggle with this sector because these equities rise and fall not on revenue or earnings, but the success of clinical trials. It has real products. Ocugen has responded to Health Canada regarding deficiencies identified with its regulatory filing for Covaxin. You never know when they will suddenly go on a squeeze. What should investors do now? Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Nasdaq Maybe. The generic form of brimonidine, the active ingredient, is not approved for the condition, according to Ocugens most recent presentation. The Motley Fool has a disclosure policy. Looking ahead, analysts are skeptical Covaxin will provide the upside Ocugen bulls are expecting. It brings in no revenue. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. These options will be cheaper than owning the stock itself. Type a symbol or company name. Emergency Use Authorization (EUA) for Covaxin, the COVID-19 vaccine developed by Ocugen's partner, Bharat Biotech. Like other life sciences companies involved in Covid-19 vaccine. While anything is possible, I would not anticipate a miracle here. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization. CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. If youre not convinced by now, maybe you will consider OCGN stock a poor investment when looking at the fundamentals. When the market crashed during the U.S. pandemic outbreak in March, shares of vaccine makers understandably soared as work began on developing vaccines to fight COVID-19. The FDA told the company in June 2021 that it should instead follow the standard path to full approval of the vaccine in adults. Still, Ocugens balance sheet isnt as dire as its share price might suggest. Since its merger, Ocugen stock has continued the decline that occurred under the company that it took over, Histogenics. This requires no immediate effort on your part. The Motley Fool has no position in any of the stocks mentioned. Historical daily share price chart and data for Ocugen since 2023 adjusted for splits. CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants. Like Pfizer's BNT162b2 and Moderna's mRNA-1273, it requires two doses. Unfortunately for longs, OCGN is much closer to the worst of conditions. For now, though, what happens in India stays in India. From a near-term standpoint, there are two key risks. Guys, theres no revenue here! Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 4.75, with a high estimate of 8.00 and a low estimate of 3.00. The Ocugen deal is a way to salvage some limited value. Realistically, Ocugen is probably looking at potential approval of Covaxin in mid-2023 at the earliest. First, the balance sheet is in at least decent shape. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. The Motley Fool has a disclosure policy. If they invent a miracle treatment for a condition, the money will find its way to the stock. 2023 InvestorPlace Media, LLC. What Is the Best EV Stock to Buy Now? There's still a chance that the vaccine could receive a green light in Canada. Another alternative is to sell some or all of your Ocugen stock and invest the money elsewhere. But the sale of NeoCart appears to not yet have closed after its deadline was extended to allow Medavate to secure financing. Keith Speights for In 2018, its NeoCart biologic failed to meet the primary endpoint of its own Phase III trial. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Do Not Sell My Personal Information (CA Residents Only). Emergency Use . You canfollow Will on Twitterat @HealyWriting. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After encouraging preliminary results, Ocugen began trying to sell 100 million doses of the vaccine in February. Create your Watchlist to save your favorite quotes on Nasdaq.com. Start trading Options with Saxo today. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. These symbols will be available throughout the site during your session. Investors need to understand the risk profile here. Cassava Sciences (NASDAQ:SAVA) has soared 454% in just the last three months. Not an offer or recommendation by Stocktwits. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Still, this stock is cheap for reasons that my colleague Josh Enomoto spelled out well. It has real management. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Ocugen. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. Histogenics itself highlights the risks involved in small-cap biotech. Investors were hopeful that the small drugmaker would be able to win U.S. 7 Travel Stocks to Buy Banking On Pent-Up Demand. The Motley Fool has no position in any of the stocks mentioned. Learn More. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days later. As of 1:37 p.m. EST, the biopharmaceutical company's stock price was down more than 15%.. However, due to the fact the details of the definitive agreement have yet to be finalized, in addition to the current lack of insight into the U.S. regulatory pathway or commercial strategy, Ramakanth stays on the sidelines for now. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Matthew McCall left Wall Street toactually helpinvestors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. Ocugen Inc. stock rises Wednesday, outperforms market Feb. 22, 2023 at 5:14 p.m. But the allure of the space is that when a company wins, its shareholders win big. Ocugen had to go an unusual route to go public. However, the Strong Buy consensus rating is backed with a $0.9 price target, which implies downside of 68% from current levels. All rights reserved. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. The company does not earn revenue, relying on grants, a dwindling cash position, and stock dilution to keep its doors open. Conditions have only become worse since that time. The vaccine reportedly has a 78% efficacy rate against COVID-19, significantly lower than leading vaccines granted FDA emergency authorization. The stock ultimately hit its 2020 low on June 1 at a price of just 17 cents. It means that institutional investors focused on the sector largely have passed on the pipeline. The steep decline came after the company announced that the U.S. Food and Drug Administration (FDA) won't grant Emergency Use Authorization (EUA) for COVID-19 vaccine Covaxin in children ages two to 18. You can be a growth investor, futures trader, deep-value investor, a day trader, options player, or a dividend aficionado. It's likely that the company will take longer to file for full FDA approval of the vaccine than Moderna will. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Written by Shares declined 85% in three sessions around the closing of the merger, which also included a 1-for-60 reverse stock split. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. The stock had gained some traction after they announced the. But theres a big difference in having an edge flipping sub-$5 stocks vs. combing over this group as an investor looking for sound fundamentals and a mistakenly low stock price. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. Hold) without suggesting a price target. Nor should one look forward to OCGN stock to becoming the next GW Pharmaceuticals (NASDAQ:GWPH) or Cara Therapeutics (NASDAQ:CARA). The statistics support having long-term exposure to this asset class. Do not expect this to become the biotech who made good like Biogen (NASDAQ:BIIB). Ocugen isnt a promotional, fly-by-night penny stock. From the outside looking inward, it looks like a marriage of two people who got together simply because nobody else would take them. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. The OCGN stock forecast 2022 outlook suggests that Ocugen's stock may struggle in the short term. So, what goes wrong? The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. All rights reserved. Copy and paste multiple symbols separated by spaces. See disclosure here. That pathway will likely require the company to conduct further clinical testing of the vaccine in the U.S. Are there any other near-term catalysts for the biotech stock? Ocugen estimates the drug could have as many as 63,000 potential patients. Ocugens Big Run: One company that has been a home-run investment in the last year has been biotech stock Ocugen Inc (NASDAQ:OCGN). Ocugen, previously a private company, instituted a reverse merger, which they completed on Sep. 30. The odds of Ocugen stock winding up at zero are material. Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. The Ocugen deal is a way to salvage some limited value. Without NeoCart, that burn likely comes down. I am all for a good opportunity, but I dont know why some investors insist on penny stocks. In December, Ocugen stated that it had put together an advisory board of "leading academic and industry experts to evaluate the clinical and regulatory path to approval in the U.S. After all, one cannot expect Ocugen stock to cure its ills when the company itself has fallen into critical condition. CanSinoBio is a legitimate player in the industry; the companys market cap is near $2 billion after a nice rally in recent weeks. The FDA's decision not to issue EUA really wasn't all that surprising, though. The biotech stock promptly crashed by more than 30%. The company has a gene therapy platform as well as two preclinical compounds that aim to treat retinal diseases. Ocugen stated in a press release that it plans to "continue working with the FDA to evaluate the regulatory pathway for the pediatric use of Covaxin." There's no way, however, to know what the COVID-19 vaccine market dynamics will be two years from now. Most biotech companies have intriguing stories on paper; Ocugen is no different. The S&P 500 has rallied 52.9% from the March low to its highs on August 6. The content is intended to be used for informational purposes only. Its all about choice. Considering Bharats reputation for world-class R&D and manufacturing capabilities in vaccines and bio-therapeutics, H.C. Wainwright analyst Swayampakula Ramakanth thinks the company is a suitable partner.. OCGN does not even appear to have an apparent reason to exist. Its top officers have experience at Pfizer (NYSE:PFE) and other well-respected pharmaceutical and biotechnology companies. (See OCGN stock analysis on TipRanks). For investors new to the story, there are some positives when it comes to OCGN stock. The latest closing stock price for Ocugen as of March 03, 2023 is. Type a symbol or company name. ET on Friday. Even at around 40 cents per share, I would consider Ocugen stock overvalued. 7 Penny Stocks Poised for Explosive Growth in 2023, With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. This can prove to be a costly lesson to learn. It's hard to say for sure. I will concede this: The one great thing about the stock market is there is a style for everyone. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor.